Last $0.35 HKD
Change Today +0.005 / 1.45%
Volume 180.0K
8225 On Other Exchanges
Symbol
Exchange
Hong Kong
As of 4:01 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

venturepharm laboratories (8225) Snapshot

Open
$0.36
Previous Close
$0.35
Day High
$0.36
Day Low
$0.34
52 Week High
03/3/14 - $0.53
52 Week Low
12/27/13 - $0.22
Market Cap
128.1M
Average Volume 10 Days
156.1K
EPS TTM
$-0.08
Shares Outstanding
366.1M
EX-Date
04/7/04
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENTUREPHARM LABORATORIES (8225)

Related News

No related news articles were found.

venturepharm laboratories (8225) Related Businessweek News

No Related Businessweek News Found

venturepharm laboratories (8225) Details

Venturepharm Laboratories Limited, an investment holding company, provides drug development outsourcing, new drug research, drug delivery, clinical research, product registration, and marketing and sales services for biotechnology and pharmaceutical companies. The company engages in the research, development, and production of new drug preparation, raw materials, supplementary materials, biodrugs, natural drugs, and synthetic drugs; manufacture and sale of active pharmaceutical ingredients products; technological transfer of and services for the research and development of biodrugs, natural drugs, and synthetic drugs; and pharmacodynamic and clinical research of drugs. It also offers clinical research services, including phase I clinical and bioequivalence studies, phase II-III clinical studies, phase IV post-marketing clinical studies, data management and medical statistics, and medical administration related services; pre-clinical research services; Venturepharm-discovery services; and pharmaceutical development, contract research, and regulatory affairs services. The company provides its products and services in various therapeutic areas, such as endocrine, CNS, cardiovascular disease, dermatosis, cancer, AIDS, allergy, and antibiotics. Venturepharm Laboratories Limited offers its products under Venturepharm brand in the People's Republic of China and VPS-CRO brand internationally. The company was founded in 1998 and is based in Beijing, the People's Republic of China.

Founded in 1998

venturepharm laboratories (8225) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

venturepharm laboratories (8225) Key Developments

Venturepharm Laboratories Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Venturepharm Laboratories Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported turnover of RMB 2,893,000 compared to RMB 9,378,000 a year ago. Loss from operations was RMB 1,042,000 compared to RMB 511,000 a year ago. Loss before income tax was RMB 1,803,000 compared to profit before income tax of RMB 863,000 a year ago. Loss attributable to equity holders of the company was RMB 1,803,000 or 0.15 cent diluted per share compared to profit attributable to equity holders of the company of RMB 863,000 or 0.39 cent diluted per share a year ago.

Venturepharm Laboratories Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Venturepharm Laboratories Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported turnover of RMB 1,299,000 compared to RMB 1,827,000 a year ago. Loss from operations was RMB 1,317,000 compared to RMB 2,690,000 a year ago. Loss before taxation was RMB 1,705,000 compared to RMB 5,045,000 a year ago. Loss attributable to equity holders of the company was RMB 1,705,000 or 0.14 cent diluted per share compared to RMB 5,045,000 or 0.90 cent diluted per share a year ago. For the six months, the company reported turnover of RMB 4,192,000 compared to RMB 11,205,000 a year ago. Loss from operations was RMB 2,360,000 compared to RMB 3,201,000 a year ago. Loss before taxation was RMB 3,509,000 compared to RMB 4,182,000 a year ago. Loss attributable to equity holders of the company was RMB 3,509,000 or 0.29 cent diluted per share compared to RMB 4,166,000 or 0.51 cent diluted per share a year ago. Net cash used in operating activities was RMB 36,000 against negative net cash used in operating activities of RMB 2,071,000 a year ago.

Venturepharm Laboratories Ltd. Provides Earnings Guidance for the Year Ended December 31, 2013

Venturepharm Laboratories Ltd. provided earnings guidance for the year ended December 31, 2013. The company announced that based on the preliminary estimate of the company's management, a loss will be recorded by the company for the year ended December 31, 2013 compared with the profit recorded by the company for the year ending December 31, 2012. Based on the analysis of the information available for the time being, the Board considers that the anticipated loss after tax for the year ended December 31, 2013 was primarily attributable to: i) the loss on fair value caused by the re-valuation of convertible notes; ii) the financial expenses; iii) the loss of business for terminated PDS (Product development services), including inventory impairment and customer claims. The company has yet to finalize the annual results of the Group for the year ending December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8225:HK $0.35 HKD +0.005

8225 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8225.
View Industry Companies
 

Industry Analysis

8225

Industry Average

Valuation 8225 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTUREPHARM LABORATORIES, please visit www.venturepharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.